EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeted degradation of c-Myc through the midnolin–proteasome pathway

Jingyuan Zhao iD, Huanhuan Wu iD, Han Yu iD, Chenyu Li iD, Yuling Mao iD, Hong Yuan iD, Shuai Li iD

Proceedings of the National Academy of Sciences · 2026

DOI: 10.1073/pnas.2520128123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Jingyuan Zhao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory Center, Central Hospital of Dalian University of Technology, Dalian 116011, China. Hauptthemen laut MEDLINE: Proteasome Endopeptidase Complex, Proto-Oncogene Proteins c-myc, Proteolysis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted protein degradation (TPD) has emerged as a promising therapeutic strategy; however, most TPD technologies employ either the ubiquitin–proteasome system or the lysosomal degradation system. Here, we report the development of midnolin-based targeting chimeras (MbTACs), a ubiquitin-independent TPD that degrades target proteins. We designed and synthesized peptide-based MbTACs, which are multifunctional molecules containing c-Myc-recognition moieties and midnolin binding moieties. MbTACs promote the formation of a ternary complex consisting of the target protein, MbTACs, and midnolin via chemically induced proximity; subsequently, midnolin recruits the proteasome to degrade the target protein. Biological evaluations demonstrated that the MbTACs could degrade c-Myc effectively through the midnolin–proteasome pathway. The antitumor effects of MbTACs were further validated in vitro and in vivo. Collectively, our results provide a ubiquitin-independent TPD tool. MbTACs represent a conveniently developed modular peptide degradation chimera and have the potential to be widely used in disease therapy. We expect the MbTACs to provide a dimension for TPD design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proteasome Endopeptidase ComplexProto-Oncogene Proteins c-mycProteolysisAnimalsHumansProteolysis Targeting ChimeraUbiquitinMiceCell Line, TumorSignal TransductionPeptides

Stichwörter der Autor:innen

MbTACsc-Mycmidnolintargeted protein degradation (TPD)

Substanzen

Proteasome Endopeptidase ComplexProto-Oncogene Proteins c-mycProteolysis Targeting ChimeraUbiquitinPeptides

Autor:innen und Institutionen

  • Clinical Laboratory Center, Central Hospital of Dalian University of Technology, Dalian 116011, China.
  • Laboratory Medicine College of Dalian Medical University, Dalian 116044, China.
  • The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.
  • School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.

ORCID-Profile: Jingyuan Zhao, Huanhuan Wu, Han Yu, Chenyu Li, Yuling Mao, Hong Yuan, Shuai Li

Zitieren

APA

Zhao, J., Wu, H., Yu, H., Li, C., Mao, Y., Yuan, H., & Li, S. (2026). Targeted degradation of c-Myc through the midnolin–proteasome pathway. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2520128123

Vancouver

Zhao J, Wu H, Yu H, Li C, Mao Y, Yuan H, et al. Targeted degradation of c-Myc through the midnolin–proteasome pathway. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2520128123

BibTeX
@article{Zhao2026,
  author = {Zhao, Jingyuan and Wu, Huanhuan and Yu, Han and Li, Chenyu and Mao, Yuling and Yuan, Hong and Li, Shuai},
  title = {Targeted degradation of c-Myc through the midnolin–proteasome pathway},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  doi = {10.1073/pnas.2520128123}
}
Kostenlos starten →